SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.26+0.2%9:34 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (12324)11/23/1999 7:28:00 PM
From: aknahow  Read Replies (2) of 17367
 
5990082 Must be NON NOVEL PATENT deals with LBP. Probably of no importance and no interest.

SUMMARY OF THE INVENTION

The present invention is based on the discovery that lipopolysaccharide binding protein (LBP), an agent previously
thought to be stimulatory of the adverse effects of bacteria and their endotoxin, can actually reduce the inflammatory
potential of bacteria and their endotoxin when administered to certain subjects prior to exposure to the bacterial
endotoxin. In particular, the invention relates to the administration of LBP in an amount effective to inhibit the adverse
effects of bacterial endotoxin to a subject who has a circulating level of LBP in the normal range as measured by a
quantitative LBP assay. The LBP is administered at a time prior to exposure to bacterial endotoxin (i.e., when the subject
will be at risk of such exposure). Such times of "at risk of exposure to endotoxin" include circumstances or conditions
associated with increased translocation of gut associated bacteria and endotoxin, particularly prior to surgery. Thus, these
subjects are administered prophylactic doses of LBP, to raise the circulating LBP levels to therapeutically effective
amounts, in advance of exposure to bacterial endotoxin. The invention thus provides a method of protection against the
adverse effects of bacterial endotoxin at a time prior to endotoxin challenge/exposure.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News